Related references
Note: Only part of the references are listed.Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients
Yan-Fu Zheng et al.
WORLD JOURNAL OF CLINICAL CASES (2021)
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
Takashi Motohashi et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2021)
Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer
Seiko Bun et al.
SUPPORTIVE CARE IN CANCER (2018)
Immune regulation by glucocorticoids
Derek W. Cain et al.
NATURE REVIEWS IMMUNOLOGY (2017)
A comparison of overall survival with 40 and 50 mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data
Masahiko Nakayama et al.
GYNECOLOGIC ONCOLOGY (2016)
Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
Noriyuki Yokomichi et al.
HUMAN CELL (2013)
Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study
Vita Leonardi et al.
ONCOLOGY LETTERS (2010)
Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling
G. Mangili et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group
Noriyuki Katsumata et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study
Mark Hackbarth et al.
SUPPORTIVE CARE IN CANCER (2008)
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)
D. Lorusso et al.
ANNALS OF ONCOLOGY (2007)
Release of doxorubicin in sweat:: first step to induce the palmarplantar erythrodysesthesia syndrome?
U Jacobi et al.
ANNALS OF ONCOLOGY (2005)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies
RD Drake et al.
GYNECOLOGIC ONCOLOGY (2004)
The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma
KL Molpus et al.
GYNECOLOGIC ONCOLOGY (2004)
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
M Markman et al.
GYNECOLOGIC ONCOLOGY (2000)
Share Paper
